Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004926 · ClinicalTrials.gov registry record · Phase 1
ILX23-7553 in Treating Patients With Solid Tumors That Have Not Responded to Previous Therapy
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00004926: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00004926 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004926, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: ILX23-7553 may help solid tumor cells develop into normal cells. PURPOSE: Phase I trial to study the effectiveness of ILX23-7553 in treating patients who have solid tumors that have not responded to previous therapy.
Interventions
- DIETARY_SUPPLEMENT vitamin D3 analogue ILX23-7553
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-10 |
| Est. Completion | 2009-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004926
The ClinicalTrials.gov registry entry for NCT00004926 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which vitamin D3 analogue ILX23-7553 is the first listed.
NCT00004926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004926 about?
NCT00004926 is a clinical study titled "ILX23-7553 in Treating Patients With Solid Tumors That Have Not Responded to Previous Therapy". RATIONALE: ILX23-7553 may help solid tumor cells develop into normal cells. PURPOSE: Phase I trial to study the effectiveness of ILX23-7553 in treating patients who have solid tumors that have not responded to previous therapy.
What is the current status of trial NCT00004926?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-10. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00004926?
The interventions under investigation include: vitamin D3 analogue ILX23-7553 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00004926?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.